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β-Lactamases (BLs) able to hydrolyze β-lactam antibiotics and more importantly the last resort 
carbapenems, represent a major mechanism of resistance in Gram-negative bacteria showing multi-
drug or extensively drug resistant phenotypes. The early detection of BLs responsible of resistant 
infections is challenging: approaches aiming at the identification of new BLs inhibitors (BLI) can thus 
serve as the basis for the development of highly needed diagnostic tools. Starting from benzo-[b]-
thiophene-2-boronic acid (BZB), a nanomolar inhibitor of AmpC β-lactamase (Ki = 27 nM), we have 
identified and characterized a set of BZB analogues able to inhibit clinically-relevant β-lactamases, 
including AmpC, Extended-Spectrum BLs (ESBL), KPC- and OXA-type carbapenemases and metallo-
β-lactamases (MBL). A multiligand set of boronic acid (BA) β-lactamase inhibitors was obtained using 
covalent molecular modeling, synthetic chemistry, enzyme kinetics and antibacterial susceptibility 
testing. Data confirmed the possibility to discriminate between clinically-relevant β-lactamases on the 
basis of their inhibition profile. Interestingly, this work also allowed the identification of potent KPC-2 
and NDM-1 inhibitors able to potentiate the activity of cefotaxime (CTX) and ceftazidime (CAZ) against 
resistant clinical isolates (MIC reduction, 32-fold). Our results open the way to the potential use of our 
set of compounds as a diagnostic tool for the sensitive detection of clinically-relevant β-lactamases.
Antibiotic resistance is a serious concern in hospital and community settings. Production of β-lactamases (BLs) 
is a prevalent resistance mechanism in bacterial infections and a threat to the available antibiotic armamentar-
ium1–3. Novel BLs inhibitors are needed as well as a rapid clinical detection of BLs: the early recognition of resist-
ant organisms can guide the assessment of the best treatment.
Nowadays more than 1,300 unique β-lactamases have been identified4, comprising serine BLs (classes A, C, 
D)5 and metallo BLs (MBLs, class B)6. The emergence, in particular, of KPC-type enzymes resistant to colistin7–9, 
CTX-M type associated with resistance to quinolones and aminoglycosides10 and with blaNDM-1-carrying plas-
mids11, AmpC enzymes of which overproduction is coupled with other resistant mechanism (efflux pumps and 
OprD porin loss)12 and VIM- and NDM-type associated with multiple resistance determinants on narrow and 
broad host-range plasmids13 led to the diffusion of multi-drug resistant (MDR) pathogens, and the emergence 
of extensively drug or pan-drug resistant isolates, significantly narrowing the antibiotic treatment options14,15.
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In the last years, several new β-lactamase inhibitors entered clinical trials or received FDA-approval, including 
diazabicyclooctanes (avibactam, relebactam and nacubactam) and the boronic acid vaborbactam (RPX7009). 
The latter class of BL inhibitors covalently and reversibly inhibit serine-BLs and revert β-lactam resistance in 
BL-producing bacteria. The new antimicrobial combination with meropenem and the boronic acid BL inhib-
itor vaborbactam received FDA approval in August 201716. Some boronic acids were also shown to inhibit 
the metallo-β-lactamases (MBLs), thus opening the way for the development of pan-β-lactamase inhibitors17. 
Boronic acids possess high potentiality for the development of useful therapeutics18–23 but also represent a valid 
tool for the early phenotypic detection of BLs produced by clinical isolates. Boronic acids inhibitors are already 
used for BLs detection in phenotypic tests (agar-diffusion combo tests)24–26 with other methods such as microar-
ray profiles DNA detection27, chromogenic tests28 and double-disk diffusion test29,30.
However, if phenyl-boronic acid (PBA) and its analog 3-amino-phenyl-boronic acid (APBA) have been 
reported for diagnostic application in hospital setting31,32, the method has critical limits: boronic acids tend to 
bind saccharides and react unselectively with proteases33,34. Thus, the use of boronic acids in diagnostic tests 
useful for BLs detection in clinical samples show an important margin for improvement. Our approach relies 
on the substitution of a single boronic acid reagent by a set of ligands with fine-tuned properties to allow a more 
sensitive and informative BL detection test to be implemented. The ability of single compounds in a multi-ligand 
set to inhibit specific BLs with different potencies would potentially allow to discriminate between various types 
of clinically-relevant BLs produced by a clinical isolate via the analysis of the resulting inhibition profile.
In this context, we report the characterization of a set of benzo[b]thiophene-2-boronic acid derivatives show-
ing differentiated inhibition profiles towards clinically relevant BLs. Selected boronic acids were then investigated 
for their potential application in phenotypic tests for the simple and sensitive detection of the production of 
various β-lactamases in clinical isolates24,25.
The multi-ligands set concept has a valuable diagnostic application. In this regard, a panel of clinically-relevant 
BLs was selected for this study and include CTX-M-15 ESBL, the KPC-2 and OXA-24 carbapenemases, 
AmpC-type enzymes and the NDM-1 and VIM-2 MBLs.
For the characterization and validation of a multi-ligand set, we followed a two-step strategy. First, an 
inhibitor-ligand discovery approach integrated with organic chemistry, covalent modeling and enzymatic tests 
allowed the selection of compounds with distinctive inhibition profile. An ad hoc modified version of FLAPdock 
algorithm implemented in the software FLAP and based on GRID Molecular Interaction Fields (MIFs)35–37 was 
used to characterize the covalent binding profile of the compound set against serine-BLs and the non-covalent 
binding towards metallo-BLs. The in silico inhibition profile obtained for each compound was confirmed in vitro 
with enzyme assays. Second, these compounds were evaluated for their ability to act synergistically with various 
β-lactam antibiotics to validate their potential use in phenotypic BL detection tests. A set of clinical isolates 
producing various BLs was used to test the synergistic activity of selected compounds with the third-generation 
cephalosporins ceftazidime and cefotaxime (Fig. 1). Interestingly, acyclic boronic acid derivatives are for the 
first time reported to inhibit metallo-β-lactamases, mimicking the transition state analogues via a non-covalent 
binding mode.
The comparison of the enzyme inhibition profile of each compound with its synergistic activity in susceptibil-
ity assays allowed the final selection of compounds in the multi-ligand set.
Results
Selection and synthesis of benzo[b]thiophene-2-boronic acid derivatives. Starting from a pre-
viously reported boronic acids library active vs AmpC with nanomolar potency22 we selected a series of six BZB 
derivatives of compound 1 (Table 1a), decorated with substituents different for size and properties. The two posi-
tions of derivatization, i.e. C5 and C7, were selected according to AmpC BL binding site structural properties 
and to synthetic accessibility38. The C5 position was previously reported to primarily affect the pharmacokinetic 
rather than the affinity towards AmpC BL22. For the C5 serie in the present work we effectively optimized the 
chemical synthesis, designing a more suitable protocol (SI Scheme S1A)22,39. For C7 derivatives, in turn, three 
BZB derivatives were obtained via a new synthetic scheme by introducing bulkier substituent (compounds 4,5 
and 6) (SI Scheme S1B).
Inhibition profile of boronic acids towards clinically-relevant BLs. To obtain a well-characterized 
inhibition profile for each selected boronic acids against each BLs in the panel, the compounds were tested for 
Figure 1. Project Work flow.
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inhibitory activity. The protein panel included clinically- and epidemiologically-relevant β-lactamases, repre-
sentatives of each structural class (A to D), as mentioned above. Each BL was overexpressed in E. coli, purified by 
chromatography and characterized as already reported. (SI, Table S1)40–45. IC50 values were determined by meas-
uring the initial rate of hydrolysis in the presence of five different inhibitor concentrations, in two independent 
replicates (ρ < 0.05) (see Materials and Methods section) (Table 1a,b).
Among serine-BLs, the tested compounds showed the strongest inhibition against AmpC, while the weakest 
inhibition was observed for the class D carbapenemase OXA-24. Compounds 1-3 present a different profile with 
respect to compounds 4-6, being ten times more active against AmpC. In particular, compound 3 showed highest 
potency, with an IC50 of 0.16 µM. Compounds 4, 5 and 6 show activity against AmpC, with low micromolar affin-
ity. These variations could be reasonably attributed to the different structural modifications introduced at C5 (for 
1, 2 and 4) and at C7 in compounds 4, 5, 6, with the latters being significantly bulkier. The inhibition profiles ver-
sus CTX-M-15 and KPC-2 showed low micromolar IC50, i.e. 5–10 µM and 2–8 µM respectively (Table 1a,b)39. All 
compounds show lower affinity against OXA-24 with respect to the other BLs. The most promising derivatives, 
compounds 4 and 5, present IC50 of 38 and 23 µM, respectively, while the others range from 88 µM up to 132 µM. 
Interesting results were obtained with compounds 4 and 5, being active on the VIM-2 and NDM-1 MBLs, while 
maintaining inhibition of serine-BLs. Compound 6 presents an interesting inhibition profile vs the MBLs in the 
panel, with IC50 of 36 and 32 µM for NDM-1 and of 20 and 28 µM for VIM-2 respectively. Compound 3 was rather 
active on VIM-2 (IC50, 27 µM) but less on NDM-1. All other compounds were weaker inhibitors of MBLs with 
IC50 values ranging between 60 µM and 100 µM.
Modeling boronic acid derivatives interactions within serine BLs binding site through covalent 
docking. To explain the inhibition profile observed in vitro, in silico BAs-BLs interaction studies were per-
formed. Boronic acids act as transition-state analogue inhibitors18 interacting with the catalytic serine. The gener-
ated tetrahedral intermediate has similar geometry to that assumed by β-lactams when hydrolyzed by BL (Scheme 
S2). To investigate the role played by bonded and non–bonded interactions in BLs inhibition we modified the 
docking software FLAPdock to model the covalent binding of boronic acids to BLs binding site. Since the boronic 
acid core interacts with serine BLs exploiting the same covalent mechanism, the structural peculiarity of each 
BL binding site should account for the formation of additional non-bonded interactions and for the inhibition 
potency variability. The Molecular Interaction Fields (MIFs) for each selected BL binding sites were calculated 
(SI, Figure S1) representing the ligand image of each pocket, i.e. the structural and chemical requirements a ligand 
should fulfill to profitably interact with the protein. Therefore, the different MIFs depict how diverse are the bind-
ing sites of each protein, in terms of shape, hydrophobic and H-bond donor/acceptor hot spots. The FLAPdock 
predicted orientations of each compound within BLs binding sites are described below.
Inhibitors binding interaction with AmpC. AmpC presents a rather large binding site, characterized by hydropho-
bic and H-bond donor regions (SI, Figure S1a). As highlighted by the docking simulations performed on AmpC 
from P. aeruginosa (Fig. 2), the boronic group of BAs interacts extensively with the surrounding residues. The 
Figure 2. Docking poses for compounds in Table 1 in AmpC binding site (PDB code 1kdw). Residues lining 
the pocket are shown as capped sticks. Ligands are orange-coloured. Hydrogen bonds are represented by black 
dashed lines. Pictures were prepared using Pymol (http://www.pymol.org).
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whole acyl-enzyme complex is maintained in a deacetylating conformation21,46. The analysis of AmpC binding site 
reveals the presence of different hydrophobic regions, mainly in front of Tyr221. Planar compounds as 1, 3 and 
occasionally 2 can form pi-pi interactions with this residue. Interestingly, these molecules can also assume an alter-
native orientation placing the benzene ring in front of Asn152, thus allowing the formation of a dipole-quadrupole 
contact, as seen in the X-ray structure of the AmpC-BZB complex (SI, Figure S2)46. Differently from 1, com-
pound 2 assumes an intermediate conformation (Fig. 2b), allowing the methyl-bromine to make hydrophobic 
contacts with Tyr221 and the benzene to form dipole-quadrupole interactions with Asn152. Compound 3 can 
still assume alternative conformations moving from Tyr221 to Asn152 side-chains (Fig. 2c). In general, the pos-
sibility of assuming different favorable conformations can increase the entropic free energy component upon 
ligand binding and, possibly, the protein-ligand stability. The loss of freedom, on the contrary, is associated to 
an entropic and free energy cost, opposing binding and favoring dissociation47. In its best-predicted orienta-
tion compound 4 forms hydrophobic interaction with Leu119 through the tert-butyl moiety and a H-bond with 
Gln120 (Fig. 2d). The bulkier side-chain could hinder ligand entrance and allocation, reduces the ligand mobility 
and prevents the formation of pi-pi contacts with Tyr221, thus decreasing the binding affinity (IC50 3.88 µM). 
Compound 5 H-bond interacts with the carboxylic group and Asn152 side-chain and maintains the stacking 
interaction with Tyr221 (Fig. 2e). The presence of the carboxylic group affects the ligand orientation, forcing it 
to assume a more constrained pose. Compound 6 presents an orientation similar to 4 (Fig. 2f) maintaining the 
interaction with Asn152.
Inhibitors binding interaction with CTX-M-15. The active site of CTX-M-15 is notably different with respect to 
the previously described AmpC (SI, Figure S1b), while being more similar to that of KPC-2. CTX-M-15 has a 
large hydrophobic region in front of Tyr105, while the deeper portion of the pocket presents extended H-bond 
donor and acceptor areas. The boronic group, besides the covalent bond with the catalytic Ser70, is stabilized by 
H-bonds formed with the side chains of Lys73, Ser130, Asn132, Asn170, the backbone nitrogen of the same Ser70 
and, sometimes, Ser237. BAs assume an acetylating conformation21,48. Compound 1 is well positioned in the 
pocket (Fig. 3a), with the methyl group pointing to a hydrophobic region of the site. Nevertheless, no pi-pi inter-
action is formed between the benzo(b)thiophene and the phenyl of Tyr105 (as Tyr221 in AmpC). This missing 
interaction, likely related to a different architecture of the binding site, might contribute to the affinity loss of 1 
towards CTX-M-15 with respect to AmpC (IC50 6.4 µM and 0.4 µM, respectively; 18 fold decrement) (Table 1a,b). 
Moreover, while in AmpC alternative orientations of the ligands were favorably assumed via pi-pi interaction 
with Tyr221 or dipole-quadrupole contacts with Asn152, in CTX-M-15 no residue similar to Asn152 is present 
thus no additional interactions are established. Compounds 2 and 3 (Fig. 3b,c) present similar orientation and 
affinity decrease with respect to AmpC. Compound 4 (Fig. 3d) properly orients its aromatic ring towards Tyr105 
forming a pi-pi contact and occupying the main hydrophobic MIF of the binding site (IC50 4.49 µM). Favorable 
contacts are also formed by 5, which interacts through the carboxylic moiety with Thr216, Lys234 and Thr235 
(Fig. 3e). Nevertheless, with respect to compounds 4 the favorable stacking with Tyr105 is lost (IC50 9.4 µM). Less 
Figure 3. Docking poses for compounds in Table 1 in CTX-M-15 binding site (PDB code 4hbt). Residues 
lining the pocket are shown as capped sticks. Ligands are orange-coloured. Hydrogen bonds are represented by 
black dashed lines. Pictures were prepared using Pymol (http://www.pymol.org).
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favorable appears the orientation of compound 6 within CTX-M-15 pocket (Fig. 3f). The tert-butyl moiety par-
tially occupies the hydrophobic area in front of Tyr105 and the amidic nitrogen is possibly involved in a H-bond 
with Tyr105 aromatic ring (IC50 9,80 µM, Table 1a,b)49.
Inhibitors binding interaction with KPC-2. KPC-2 presents folding and pharmacophoric properties similar 
to CTX-M-15 (SI, Figure S1b, c). Trp105, like in CTX-M-15, plays a critical role in ligand binding and in the 
broad-spectrum activity of KPC-2 carbapenemases50. Again, the compounds are oriented in an acetylating con-
formation21. The boronic group is covalently bound to the catalytic Ser70 and is stabilized by H-bonds with 
Lys73, Ser130, Glu166, Asn170 and Thr237. Compounds 1, 2 and 3 show similar orientations, with respect to 
CTX-M-15. Compound 1 locates the methyl moiety on the hydrophobic field generated by Trp105 and main-
tain similar affinity as in CTX-M-15 (Fig. 4a, IC50 5.9 µM). Compound 2 locates the methyl bromine moiety in 
the same region (Fig. 4b, IC50 4.7 µM). Compound 3 assumes two possible orientations, with the amino moiety 
interacting with the backbone carbonyl of Cys238 (Fig. 4c; IC50 7.3 µM). No proper pi-pi contact is formed with 
Trp105. In general, the loss of stable hydrophobic interactions and the absence of Asn152, normally involved in 
dipole-quadrupole contacts with aromatic moieties, could be responsible for the lower affinity of compounds 1, 2 
and 3 towards class A BLs with respect to class C (Table 1a,b). Compound 4 assumes an orientation similar to that 
in CTX-M-15 (Fig. 4d), while 5 interact extensively through the carboxylic moiety with residues Thr216, Arg220, 
Thr235 and Thr237 (Fig. 4e, IC50 8.22 µM and 5.38 µM, respectively). H-bond contacts are as well undertaken by 
compound 6 carbonyl moiety with Ser130 and Thr235 side-chains (Fig. 4f; IC50 = 2.25 µM).
Inhibitors interaction with OXA-24. With respect to class A and C BLs, OXA-24 (class D), has a larger and more 
hydrophobic binding site (SI, Figure S1d), moreover no aromatic residues are properly oriented to form pi-pi 
contacts with the ligands. All compounds are stabilized by the formation of a covalent contact between the cata-
lytic Ser81 and the boronic group, involved in further H-bonds with Ser81 and Trp221 backbone nitrogens. The 
acetylating orientation of CTX-M-15 and KPC-2 is maintained. Nevertheless, the boronic group, because of the 
different binding site architecture, undertakes fewer contacts. Compounds 1 and 2 assume similar orientations 
(Fig. 5a,b), fitting the hydrophobic contours, but not directly interacting with any residue, which turns in a poorer 
affinity (IC50 113 µM and 93 µM, respectively). Compound 3 moves towards Leu127, to make a H-bond through 
the charged amino group, but away from the more hydrophobic region of the pocket (Fig. 5c; IC50 132 µM). 
Higher affinity was observed for 4 and 5 (Figs 5d, 7e). Compound 4 shows a favorable orientation being able 
to H-bond to Tyr112 and to form hydrophobic interactions with Trp221 and Met223 via the tert-butyl group. 
Compound 5 is able to fit the hydrophobic contours provided by Trp115 and Val130 and to H-bond, through the 
carboxylic moiety, the hydroxyl group of Tyr112. Compound 6 assumes an orientation similar to 3 and forms 
H-bonds with Ser219 and Arg261, while hydrophobic interactions are lost (Fig. 5f; IC50 88 µM). In general, the 
absence of relevant hydrophobic interactions and the lower number of contacts made by the boronic acid moiety 
might contribute to the loss of activity towards OXA-24, with respect to the previously analyzed BLs.
Figure 4. Docking poses for compounds in Table 1 in KPC-2 binding site (PDB code 3rxx). Residues lining 
the pocket are shown as capped sticks. Ligands are orange-coloured. Hydrogen bonds are represented by black 
dashed lines. Pictures were prepared using Pymol (http://www.pymol.org).
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Through modeling we rationalized, for each ligand in the set, at the molecular level, the inhibition against the 
different serine BLs in the panel.
Modeling boronic acid derivatives interactions within MBL binding site.  For the first time acyclic 
BAs are seen to extend their inhibitory affinity also vs MBLs, clearly suggesting that there is space to implement 
Figure 5. Docking poses for compounds in Table 1 in OXA-24 binding site (PDB code 3fv7). Residues lining 
the pocket are shown as capped sticks. Ligands are orange-coloured. Hydrogen bonds are represented by black 
dashed lines. Pictures were prepared using Pymol (http://www.pymol.org).
Figure 6. Docking poses for compounds in Table 1 in NDM-1 binding site (PDB code 3q6x). Residues lining 
the pocket are shown as capped sticks. Ligands are orange-coloured. Hydrogen bonds are represented by black 
dashed lines. Pictures were prepared using Pymol (http://www.pymol.org).
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the affinity towards NDM- and VIM-type enzymes. For mechanistic reasons, the interaction of the boronic acids 
with NDM-1 and VIM-2 was modeled according to the mechanism of action reported by Brem et al. for cyclic 
boronic acids. This implies a nucleophilic attack by a hydroxide, bridging the two zinc ions in ground state struc-
tures, on the boron and the generation of a tetrahedral intermediate. The IC50 estimated for the compounds 
towards the two analyzed MBL are generally higher with respect to those observed for serine BL, with the excep-
tion of OXA-24. The lack of a covalent bond replaced by coordination interaction between the enzyme and the 
compounds likely explain this fall of inhibition activity.
Inhibitors binding interaction with NDM-1. Both NDM-1 and VIM-2 present an overall similar fold 
and comparable hydrogen-bond donor and acceptor residues but different hydrophobic regions, the latter being 
quite larger in VIM-2 (SI, Figure S1e,f).
Compounds 1 and 2 have a very similar binding mode and inhibition potencies towards NDM-1 (68.40 µM 
and 64.60 µM, respectively). In our models, the boronic group was coordinating the two zinc ions, with H-bonds 
being formed between compound 1 and residues Asp124 and His189, while compound 2 interacts with residues 
Lys211 and His250 (Fig. 6a and b). The methyl and methyl bromine moieties are located in a small hydrophobic 
patch delimited by Ile35, Met67 and Val73. Compound 3 forms a salt bridge interaction with Asp212, but moving 
in this direction loses any possible hydrophobic contact and the binding to one of the zinc ions. Accordingly, the 
inhibition potency slightly increases (IC50 equal to 60.70 µM; Fig. 6c). Compound 4, 5 and 6 coordinates both 
metals in the same way as compounds 1 and 2. Compound 4 (Fig. 6d) locates its tert-butyl moiety in a small 
hydrophobic region delimited by Ile35 but is not able to properly reach Lys211 that is, instead, salt bridged by 
compound 5 (Fig. 6e). Docking simulations suggested a possible alternative orientation for compound 5, in which 
the carboxylic moiety directly coordinates one of the metals (not shown in the picture). Compound 6 is able to 
hydrogen bond to Asn220 and, differently from the two previous compounds, shows higher IC50 (102.60 µM; 
Fig. 6f).
Inhibitors binding interaction with VIM-2. As mentioned, VIM-2 shows a binding site character-
ized by larger hydrophobic areas, mainly given by Phe42 and Tyr47, not present in NDM-1 (SI, Figure S1e,f). 
Compounds 1 and 2 present the same orientation and very similar IC50 values (72.00 µM and 83.50 µM, respec-
tively). The boronic group coordinates the zinc ions through the deprotonated hydroxide and forms further inter-
actions with His94, Asp98 and His159, also involved in the metals coordination. Pi-pi interactions are formed 
between the benzo(b)thiophene and the Phe42 side chain. The methyl and the methyl bromine moieties occupy 
the hydrophobic regions defined by the same residue (Fig. 7a and b, respectively). The ligand, and in particular the 
boronic group, present a quite similar orientation to that found by Brem et al. for cyclic boronates in VIM-2 (PDB 
code: 5FQC)17. Compound 3 presents an orientation within the pocket opposite to that of compound 1, likely 
induced by the formation of a salt bridge between the protonated amine and Glu126. This additional interaction, 
besides the coordination and hydrogen bonds given by the boronic group, could explain the higher affinity of this 
Figure 7. Docking poses for compounds in Table 1 in VIM-2 binding site (PDB code 2yz3). Residues lining 
the pocket are shown as capped sticks. Ligands are orange-coloured. Hydrogen bonds are represented by black 
dashed lines. Pictures were prepared using Pymol (http://www.pymol.org).
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compound (Fig. 7c; IC50 26.90 µM). Similar inhibition values were also measured for compounds 4 and 5, both 
able to hydrogen-bond Arg185 (Fig. 7d,e). In particular, compound 4 moves towards Arg185 forming a double 
contact through both the thiophen sulfur and the ester carbonyl. The metals coordination is maintained but the 
interactions with His94 and Asp98, as well as the pi-pi contact with Phe42, are lost. Compound 5 interacts with 
both the side chain of Arg185 and the backbone amide of Asn190 by means of the carboxylic moiety, still main-
taining the pi-pi interaction with Phe42. Compound 6 assumes an orientation similar to compound 4 contacting 
Arg185 through the boronic group, keeping the metal coordination but not forming any other significant contact. 
This compound shows the weaker inhibition towards VIM-2 (Fig. 7f; IC50 102.60 µM).
Evaluation of the synergistic activity of selected compounds. In order to evaluate the usefulness 
of selected compounds for the design of phenotypic tests, and further support the results of the modeling and 
enzyme studies, we investigated the potential of boronic acids to inhibit bacterial β-lactamases in a whole-cell 
assay by acting in synergy with β-lactam antibiotics. As previously reported22,46, no antibiotic effect was detected 
for boronic acid alone (MIC higher than 128 μM). Compounds were tested for synergy in association with 
third-generation cephalosporins currently in therapy: ceftazidime (CAZ) against eight clinically isolated bacteria 
overproducing AmpC BL, and cefotaxime (CTX) against five clinically isolated bacteria strains hyperproduc-
ing CTX-M-15, KPC-2, NDM-1, VIM-2 and OXA-24 BLs (collection of the Spanish Network for Research in 
Infectious Pathology (REIPI, Spain), Table 2a,b). Selected strains naturally overexpressed the BLs in the panel, 
allowing the biological validation of the results obtained in the recombinant proteins assays. The minimum inhib-
itory concentrations (MICs), for CAZ and CTX alone and in combination with boronic acids against resistant 
strains were determined (Table 2a,b). Starting from isolates overproducing AmpC, the MIC of CAZ alone ranged 
from 512 µg/mL to 64 µg/mL (Table 2a,b)51. In combination with the BAs, the MIC values of CAZ decreased in 
several cases, by a minimum of 4 fold to a maximum of 32 fold for the best case.
The best overall results were achieved with E. coli, E. aerogenes and P. aeruginosa strain 148. Analyzing each 
BA alone, for the combination CAZ/1, MICs improvement were always evident vs all considered clinical strains 
overproducing AmpC (from 4 fold up to 32 fold). 1 was able to restore the susceptibility of all strains overproduc-
ing P. aeruginosa. For the CAZ/2 combination, 2 resulted slightly more active than 1 on the DHA-1-producing 
E. coli strain (16 fold vs 8 fold). Restoration of susceptibility against P. aeruginosa strains was evident as for com-
pound 1. On the contrary, no synergy was detected for the CAZ/2 combination towards E. cloacae, while the asso-
ciation with 1 gave a 4-fold MIC decrease. Other derivatives (3, 4-6) showed, in general, poorer synergic effect 
with CAZ (16 fold, less or no MIC reduction). The only exception was compound 3, reducing MIC by 32 fold on 
the AmpC hyperproducer E. coli strain and by 16 fold vs P. aeruginosa strain 148. The effect of the combination 
of the described BAs with CTX against six strains producing class A, B, C and D β-lactamases is more complex 
(Table 2a,b). The MIC of CTX for these pathogens ranged from 1024 to 64 µg/mL. Again, compounds 1 and 2 
resulted the most active. Both compounds were able to improve CTX activity with almost all strains producing 
class A, B, C and D BLs, particularly in P. aeruginosa and K. pneumoniae (16 and 32 fold MIC reduction respec-
tively). Only in the case of E. coli producing CTX-M-15 no synergic effect was detected, except for compounds 
Table 1. Chemical structure and IC50 (µM) values estimated for the compounds series towards the BLs panel: 
a - Compounds were prepared as pinacol-protected derivatives on the boronic group. The reported IC50 values 
are the mean values of two replicates for each tested inhibitor concentration value; the STDs were calculated by 
Student’s t-test considering a 95% of confidence range (ρ < 0.05); b - b. Heat-map representation of the above 
reported IC50 values.
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5 and 6 (4 fold MIC reduction). Also for compounds 3-6, best synergistic effect was achieved vs K. pneumoniae 
producing KPC-2 (32 folds improvement). 3 showed the most potent synergistic activity, with a reduction of the 
MIC value up to 128-fold with all considered bacterial strains, except with CTX-M-15-producing E. coli. Overall, 
results for compounds 4, 5 and 6 showed a null or very low effect, with the exception of compounds 5 and 6, 
which gave the best performance towards A. baumannii strain producing OXA-24.
Interestingly, the synergistic activity of each selected BL inhibitor correlates to a certain extent with the inhi-
bition potency measured with purified enzymes, also considering the difficulties in working with clinical strains, 
which commonly present additional resistance mechanisms, such as porins, efflux pumps etc. The distinctive 
activity profile of each compound in the panel could represent the basis for the design of a phenotypic test allow-
ing the detection of specific types of clinically-relevant β-lactamases directly in clinical isolates.
Discussion
Six selected boronic acids were evaluated for their inhibitory activity against clinically-relevant serine- and 
metallo-β-lactamases, as well as their potential usefulness for the design of detection tool to be used in the clin-
ical microbiology laboratory. To this aim, the antibacterial synergistic activity of these inhibitors was measured 
with a set of clinical isolates producing various β-lactamases, and the data compared to the enzyme inhibition 
potencies. In this respect, the boronic acids derivatives were first evaluated with enzyme assays against a panel 
of relevant BLs, then in silico, and finally with antibacterial susceptibility testing methods. From a computa-
tional point of view, the challenge of a feasible characterization of the covalent binding resulting between the 
boronic acid moiety and the catalytic serine has been addressed52,53. The formation of a reversible covalent 
bond generally increases the binding affinity to an extent lower than 20 fold. Therefore it does not always lead 
to a tighter binding and, most important, an equal contribution to the protein-ligand complex formation and 
stabilization could be given by other geometrical and non-covalent energetic factors54. In this perspective, for 
the analyzed series of boronic acids the effect of substituents could be almost as important as the effect of the 
boronic group itself as seen from the different binding affinity shown towards selected BLs. Compounds 1, 2 
and 3 show high nanomolar inhibitory potency towards AmpC (IC50 0.4 µM; 0.2 µM and 0.6 µM respectively, 
Table 1a,b). This result accounts for the higher efficacy of derivatization in position C5 with respect to C7 vs 
AmpC. As the covalent binding mechanism does not change and all AmpC-BA acyl enzymes maintain the 
same deacylating orientation, geometrical and non-covalent factors should explain variation in affinity21,46. The 
analysis of the docking results reveals in AmpC the possibility of assuming two slightly different orientations, 
Table 2. Boronic compounds panel antibacterial activity profile: a - Trending profile of antibacterial activity for 
the entire compounds library versus nine clinically isolated bacteria overproducing AmpC_BL (MIC values in 
combination with ceftazidime, CAZ,) and five clinically isolated bacteria strains producing class A (CTX-M-15, 
KPC-2), class B (NDM-1, VIM-2) and class D (OXA-24) BLs (MICs in combination with ceftazidime, CTX); b - 
Antibacterial activity heat-map: the Table shows, with a specific color scale, the MIC values trending profile for 
the entire compounds library as described above. aPlasmidic AmpC - DHA1; bOverproduction Chromosomal 
AmpC; *in combination with ceftazidime, CAZ; ** in combination with cefotaxime, CTX.
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one favoring the formation of a pi-pi contact with Tyr221 and the other forming a dipole-quadrupole inter-
actions with Asn152. This might justify the higher affinity because of a smaller entropic loss upon binding47. 
Accordingly, the presence of an aromatic system has been proven to be more critical in targeting class C BLs, 
with respect to class A. Compounds 4, 5 and 6 loose this flexibility because of the presence of bulkier substit-
uents in C7, which force ligands to move apart from Tyr221. The different inhibition trend and the positive 
effect of C5 derivatization type are clearly visible in Table 1a,b. In particular each compound shows a peculiar 
inhibition profile against the BLs in panel supporting their possible future use in combination as diagnos-
tic tools (Table 2a,b). Compounds binding to class A CTX-M-15 and KPC-2 show a similar trend (Fig. 8). 
Here the covalent bonding generates an acyl-enzyme, further stabilized by a number of H-bonds between the 
boronic group and the surrounding residues. The loss in affinity with respect to AmpC, considering in particu-
lar compounds 1, 2 and 3 (IC50 vs KPC-2 5.9 µM; 4.2 µM and 7.3 µM respectively), can be attributed to three 
interconnected aspects: (i) absence of a strong pi-pi contact, (ii) absence of a quadrupole-dipole interaction, 
(iii) reduced compound flexibility in the binding site (Table 1a,b).
For the biological evaluation of the selected boronic acids, a set of representative clinical isolates of E. coli, 
E. cloacae, E. aerogenes, P. aeruginosa, K. pneumoniae and A. baumanii, showing low susceptibility to CAZ and 
CTX, and producing the β-lactamases included in the study was obtained55. In vitro antimicrobial susceptibility 
testing showed a valuable synergistic activity of the selected compounds, although the antibiotic potentiation 
activity varied in function of the compound and the clinical isolate. Interestingly, a good correlation was observed 
between the synergistic activity and the enzyme inhibition profile of the various compounds. We compared the 
biological profile of each boronic acid versus BLs as IC50 values (Fig. 8, blue line) and bacteria as MIC values 
(Fig. 8, red line). Regarding to the several overproducing AmpC_BL bacterial strains, we selected Pseudomonas 
aeruginosa 120 as the most representative of the compounds panel efficacy in inhibiting bacterial growth. We 
consider that MIC higher than 128 µM represents low inhibitory effect on the cell growth (8 times reduction of 
CTX IC50). IC50 higher than 30 µM indicates low inhibitory effect against BL enzyme. We can observe that for 
each boronic acid under study there is a similar trend for compounds 1/5 and 2/4 considering almost all proteins 
Figure 8. In vitro results for each designed compound against the selected BLs panel: IC50 and MIC values. 
Direct comparison between IC50 (blue line) and MIC (red line) values for each inhibitor of the selected 
compounds panel versus the several beta-lactamase proteins. The obtained data results show that each inhibitor 
presents a similar trending profile supporting a good correlation between in vitro datasets. The reported error 
bars correspond to 5% value for both datasets; A – AmpC Pseudomonas aeruginosa 120; B – CTX-M-15 E. coli; 
C – KPC-2 K. Pneumoniae; D – OXA-24 A. Baumanii; E – NDM-1 E. coli; F – VIM-2 Pseudomonas aeruginosa.
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(CTX-M15, KPC-2, NMD-1 and OXA-24). They show however different potency. Compounds 3 and 6 show also 
a similar trend, but with different potency.
The distinctive inhibition profile and synergistic activity of the selected compounds could represent the basis 
for the development of a detection tool able to identify major β-lactamases, including carbapenemases, currently 
circulating in the clinical setting, although further validation is required. Nonetheless, we were able to corre-
late chemical and binding features of the inhibitors with their inhibition profile. Noteworthy, for the very first 
time, acyclic boronates derivatives were reported to inhibit MBLs via a non covalent mechanism of action. These 
results, considering their described ability to inactivate all classes of serine-β-lactamases, open the way for devel-
oping BAs as very broad spectrum inhibitors.
Summarising, the C5 derivatization favors AmpC inhibition, with compounds 1 and 2 being able to potenti-
ate the antibiotic activity towards several AmpC producing strains (Table 2; Fig. 8). Substituents in C7 position 
allowed better synergistic activity towards CTX-M-15-producing strains, while C5 derivatives gave better results 
towards OXA-24-producing A. baumannii. (Table 2; Fig. 8).
An additional relevant result of our study is represented by the ability of some compounds to potentiate the 
activity of cefotaxime on carbapenemase-producing P. aeruginosa or A. baumannii isolates, usually poorly inhib-
ited by currently available combinations, including ceftazidime-avibactam, despite their rather high clinical 
relevance56,57.
Conclusions
Boronic acids represent a known class of investigational and therapeutically valuable BLIs potentiating the activ-
ity of β-lactam antibiotics. Besides their therapeutic applications, the development of specific detection tools 
represents an additional field of application of boronic acids. From an integrated approach aiming at evaluating 
the interaction of a boronic acids set against a selected BLs panel including clinically-relevant AmpCs, ESBLs, 
serine and metallo-carbapenemases, we identified C5-substituted BZB derivatives. Covalent docking studies, 
enzyme inhibition analysis and biological evaluations were performed. The synthesized boronic acids showed 
high nanomolar affinity towards class C AmpC BL and low micromolar affinity towards class A CTX-M-15 and 
KPC-2 enzymes. Interestingly for the first time inhibition activity against MBLs (NDM-1 and VIM-2; IC50 range 
20 µM in the best case) was also detected for acyclic boronic acids: noteworthy the activity of cefotaxime on a 
VIM-2 producing P. aeruginosa isolate in microbiological assays was potentiated by 32 fold, despite their inhibi-
tion potency in vitro (IC50 values in the µM range). Docking studies supported the observed structure-activity 
relationships, confirming the predictive capability of the computational study. Indeed, a newly ad hoc covalent 
docking algorithm was implemented within FLAPdock, representing a valuable tool for investigating the inhib-
itory activity of covalently-bound inhibitors, being able to identify the chemical features responsible for the 
specific inhibition profile of the compounds towards various β-lactamases. Antimicrobial susceptibility testing 
confirmed the capability of selected compounds to act in synergy with third-generation cephalosporins against 
multidrug-resistant clinical isolates, with observed potentiation fold up to 256. The enzyme inhibition profile 
satisfactorily correlated with the synergistic activity measured in whole-cell assays.
The data presented confirmed the possibility to discriminate between clinically-relevant β-lactamases on 
the basis of the inhibition profile of each compound belonging to the designed multiligand set. Our results 
open the way to the potential use of our designed compounds set as a diagnostic tool for sensitive detection of 
clinically-relevant β-lactamases.
Material and Methods
Protein expression and purification. The P. aeruginosa AmpC β-lactamase was obtained from E. coli 
BL21(DE3) culture carrying the plasmid vector pET-9aAmpC in 1 L of LB-medium with kanamycin 50 µg/mL, 
at 37 °C, 150 RPM for 24 hrs. 3-methylaminophenylboronic acid (MAPB) was used to functionalize Affigel-10 
resin (BIORAD) as previously described58,59. In order to produce and purify the other β-lactamase enzymes, the 
β-lactamases ORFs were subcloned in various expression vectors such as pET-9a (for CTX-M-15, KPC-2 and 
VIM-2), pET-15b (for NDM-1) or pGEX-2T (for OXA-24) and introduced in Escherichia coli BL21(DE3) or 
DH5α. Culture of ZYP-5052 auto-inducing medium or SB were grown for 24 hours at 25 or 37 °C under selec-
tive condition (50 µg/ml kanamycin or 100 µg/ml ampicillin according to the vector carried by the recombinant 
strain). Cells were harvested by centrifugation (10,000 × g, 30 min, 4 °C). KPC-2, NDM-1 and OXA-24 were 
purified from the crude extract while CTX-M-15 and VIM-2, from the culture supernatant. The β-lactamases 
were purified to >95% homogeneity by ion-exchange, gel filtration or affinity chromatography adopting specific 
purification strategies using an AKTA Purifier platform (GE Healthcare, Uppsala, Sweden). Purity of the protein 
preparation was estimated by SDS-PAGE analysis and electron spray ionization mass spectrometry (ESI-MS)60. 
For each protein, kinetic profile characterization was conducted using different β-lactam antibiotics depending 
on belonging BL class; i.e. cephalothin for class A CTX-M-15, class C AmpC and class D OXA-24, ampicillin for 
class A KPC-2, imipenem for class B NDM-1 and VIM-2. A detailed description of protein purification protocols 
and protein kinetic profile characterization is given in the Supplementary Information. (SI, Table S1).
Enzyme inhibition assays. The synthesized compounds were tested against the panel of purified 
β-lactamases, i.e. AmpC, CTX-M-15, KPC-2, OXA-24, NDM-1 and VIM-2 by spectrophotometric assay, using 
a DU-640 spectrophotometer (Beckman Coulter)20. Boronic acids were dissolved in dimethyl sulfoxide (DMSO) 
stock solutions at 10 mM; more dilute stocks were subsequently prepared as necessary by dissolving them in 
50 mM phosphate buffer at pH 7.5 (DMSO ≤ 3% V/V, no inhibitory effect confirmed). Boronic acids isolated as 
pinacol-protected boronic acid were tested without further ester cleavage reaction; compounds spontaneously 
hydrolysed to the free acid form when dissolved in 50 mM phosphate buffer at pH 7.5. Assay conditions were as 
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follows: 50 mM phosphate buffer, pH 7.5; 100 µM cephalothin (sodium salt, Sigma) as reporter substrate, reaction 
monitored at 265 nm, time course 300 seconds 25 °C. The background rate of cephalothin hydrolysis was found 
to be negligible under these conditions (approximately 1%). Reactions were initiated with addition of BL enzyme 
(the concentration values for each BL enzyme into the SI, Table S1 have been reported).
Each inhibitor compound was assayed at five different concentrations, in duplicate for calculating an error 
value with 95% confidence interval (ρ < 0.05). From the resulting inhibition percentages at each different 
inhibitor concentration and, assuming a competitive inhibition for the boronic compounds panel, it was pos-
sible to calculate the IC50 values from the Dixon plot 1/V vs [I], using the equation IC50 = ((1/0.5 ∙ v0) − m)/
q61, where v0 is the rate of hydrolysis of the reporter substrate (v0 being the rate measured in the absence of 
inhibitor), q the y axis intercept and m the slope of the resulting linear regression. As previously reported for 
other boronic acid inhibitors of BLs, tested compounds were competitive inhibitors and no incubation effect was 
detected21,22. A known inhibitor was included in the compounds panel for each β-lactamase group, i.e. 3APBA 
(3-aminophenylboronic-acid) for class A, C and D serine β-lactamases (IC50 = 25 ± 1.9 µM for AmpC_BL44) and 
L-Captopril for class B β-lactamases as reference compound (IC50 = 154 ± 1.7 µM for NDM-1)62.
Molecular docking. FLAPdock is a docking approach implemented in the software FLAP35, based on 
GRID Molecular Interaction Field similarities36,63, combined with classical energetics. FLAP has been applied 
in different drug design campaigns, giving successful performances in terms of structure-, ligand- and 
pharmacophore-based virtual screening64–69. The FLAPdock method and full validation is as yet unpublished; 
hence a detailed description of the method is provided below. FLAPdock follows a molecular fragmentation 
approach, subsequent placement of each fragment in the site of the target, followed by incremental construction 
of the molecule. Ligand fragments are generated using an iterative procedure searching for substructures with 
7–12 heavy atoms and 1–3 rotatable bonds; these parameters having been chosen to provide fragments that are 
small enough to reduce the conformational space and increase the speed of the placement algorithm, and large 
enough to contain a certain level of specificity in the site. If no fragments are found, these rules are relaxed, and 
subsequently, if no fragments are found again, then the ligand is treated as a single entity. Fragment conforma-
tions are taken from the previous ligand conformational ensemble and a further RMS clustering performed to 
remove any redundancy. This approach is performed (as opposed to performing a conformational search only 
on the fragments) to focus fragment conformations toward those that are able to present once the entire ligand is 
reconstructed. Each fragment is used as a starting point for the docking, unless it is completely un-functionalized 
(i.e. it must contain a donor/acceptor/charged group). A set of poses for the starting fragment is generated using 
FLAP quadruplet alignment of the fragment conformer atom quadruplets, and the receptor site GRID MIF min-
ima points; in this way hundreds of thousands of poses are typically generated for this starting fragment. As a first 
step, the poses are scored using a weighted sum of the FLAP field similarities, including shape, donor, acceptor, 
and hydrophobic similarity. This faster scoring enables the selection of a subset of poses that are more likely to 
contain the ‘correct’ position for this fragment; typically several hundred solutions are retained per conformation, 
and therefore several thousand over the fragment ensemble. A second scoring step calculates Lennard-Jones and 
dielectric corrected Coulombic energetic terms for this subset; the solutions are then ranked according to the 
combined score and, subjected to RMS clustering, and the best scoring pose in each cluster retained. The best 
100–200 solutions from this first step (after docking all fragments) are typically retained for the subsequent phase 
(depending on user request). For each solution, the subsequent fragment is added at 12–18 random torsional 
angles. In this phase, added fragments can be quickly filtered according to any internal or external clashes, before 
scoring according to the field similarity and energetic terms. The final pool of solutions is subjected to RMS clus-
tering and filtering, followed by retaining of the top 100–200 solutions. The final phase occurs when the ligand 
is completely reconstructed; at this point the top 10 solutions are subjected to energetic optimization in the site, 
and rescored after recalculating the ligand MIFs for this conformation. Internal validation (redocking of x-ray 
ligands) has shown that one of the top five poses contains a pose within 2.0 Å of the x-ray position in more than 
90% of the cases [unpublished results]. For the work described in this paper, a modification of the approach was 
developed to simulate the covalent interaction between the β-lactamase catalytic serine and the boronic acid. The 
simulation is not trivial, due to the conformational change of the boronic acid from an sp2 to sp3 configuration. To 
do this, the library of boronic acids was imported into a virtual reaction software, and the reaction with a serine 
residue simulated to generate a library of boronic acyl-serine compounds. Within FLAPdock, each compound in 
the library was docked, where the boronic acyl-serine was subjected to the conformational preparation procedure 
outlined above; in this way the correct geometry around the boronic acid was maintained. During the fragmenta-
tion step, the serine substructure was used to generate the initial fragment (and it’s position, without scoring), and 
then the subsequent fragments from the boronic acyl-serine structure added incrementally as described above.
In the case of NDM-1 and VIM-2 the compounds were directly docked in the sp3 configuration, following the 
indication provided by Brem et al.17. The standard FLAPdock approach was used since no covalent interaction is 
formed.
Biological evaluation. Susceptibility testing was performed in Mueller Hinton broth and interpreted fol-
lowing the guidelines of the National Committee for Clinical Laboratory Standards70. To test the inhibitory activ-
ity, the compounds were dissolved in DMSO, 50% in water, and further dilutions were performed using growth 
medium. In all cases tests were performed at a final DMSO concentration below 5%, avoiding unwanted DMSO 
inhibition effect on strains growth (blank test control with DMSO were performed). The MICs of cefotaxime 
and ceftazidime alone and in association were determined against several relevant Gram-negative clinical iso-
lates, selected from the pathogen collection of the Spanish Network for Research in Infectious Pathology (REIPI; 
Spain). The selection was based on strains capability of producing β-lactamases of interest for the present study. 
The antibiotic:inhibitor ratio was 1:1 (w/w).
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Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
References
 1. Bush, K. Proliferation and significance of clinically relevant beta-lactamases. Ann. N. Y. Acad. Sci. 1277, 84–90 (2013).
 2. Farina, D. et al. The inhibition of extended spectrum beta-lactamases: hits and leads. Curr. Med. Chem. 21, 1405–1434 (2014).
 3. Tondi, D. et al. Decoding the structural basis for carbapenem hydrolysis by class A beta-lactamases: fishing for a pharmacophore. 
Curr Drug Targets 17, 983–1005 (2016).
 4. Naas, T. & Iorga, B. http://www.bldb.eu, 2015).
 5. Ambler, R. P. et al. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276(Pt 1), 269–270 (1991).
 6. Bush, K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int. J. 
Antimicrob. Agent. 46, 483–493 (2015).
 7. Livermore, D. M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64(Suppl 1), i29–36 (2009).
 8. Theuretzbacher, U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int. J. Antimicrob. 
Agents 39, 295–299 (2012).
 9. Munoz-Price, L. S. Carbapenem-resistant Enterobacteriaceae, long-term acute care hospitals, and our distortions of reality. Infect 
Control Hosp Epidemiol 34, 835–837 (2013).
 10. Hawkey, P. M. & Jones, A. M. The changing epidemiology of resistance. J Antimicrob Chemother 64(Suppl 1), i3–10 (2009).
 11. Kumarasamy, K. K. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, 
and epidemiological study. Lancet Infect Dis 10, 597–602 (2010).
 12. Rodriguez-Martinez, J. M., Poirel, L. & Nordmann, P. Molecular epidemiology and mechanisms of carbapenem resistance in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother 53, 4783–4788 (2009).
 13. Poirel, L. et al. Tn125-related acquisition of blaNDM-like genes in Acinetobacter baumannii. Antimicrob Agents Chemother 56, 
1087–1089 (2012).
 14. Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 
538–582 (2008).
 15. Tam, V. H. et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas 
aeruginosa. Antimicrob. Agents Chemother. 54, 1160–1164 (2010).
 16. FDA, New & Release. FDA approves new antibacterial drug, 2017).
 17. Brem, J. et al. Structural basis of metallo-beta-lactamase, serine-beta-lactamase and penicillin-binding protein inhibition by cyclic 
boronates. Nat Commun 7, 12406 (2016).
 18. Tondi, D. et al. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase. Chem. Biol. 8, 593–611 
(2001).
 19. Eidam, O. et al. Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo. Proc. Natl. Acad. Sci. USA 109, 
17448–17453 (2012).
 20. Tondi, D., Calo, S., Shoichet, B. K. & Costi, M. P. Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase 
inhibitors. Bioorg. Med. Chem. Lett. 20, 3416–3419 (2010).
 21. Tondi, D. et al. Targeting class A and C serine beta-lactamases with a broad-spectrum boronic acid derivative. J. Med. Chem. 57, 
5449–5458 (2014).
 22. Venturelli, A. et al. Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J. Med. Chem. 50, 
5644–5654 (2007).
 23. Rojas, L. J. et al. Boronic Acid Transition State Inhibitors Active against KPC and Other Class A beta-Lactamases: Structure-Activity 
Relationships as a Guide to Inhibitor Design. Antimicrob Agents Chemother 60, 1751–1759 (2016).
 24. Bhattacharya, S. Early diagnosis of resistant pathogens. Virulence 4, 172–184 (2012).
 25. Diekema, D. & Pfaller, M. Rapid Detection of Antibiotic-Resistant Organism Carriage for Infection Prevention. Clin Infect Dis 56, 
1614–1620 (2013).
 26. Gupta, G., Tak, V. & Mathur, P. Detection of AmpC beta Lactamases in Gram-negative Bacteria. J Lab Physicians 6, 1–6 (2014).
 27. Naas, T., Cuzon, G., Truong, H., Bernabeu, S. & Nordmann, P. Evaluation of a DNA microarray, the check-points ESBL/KPC array, 
for rapid detection of TEM, SHV, and CTX-M extended-spectrum beta-lactamases and KPC carbapenemases. Antimicrob Agents 
Chemother 54, 3086–3092 (2010).
 28. Gabay, E. L., Sutter, V. L. & Finegold, S. M. Rapid beta-lactamase testing in bacteroides. J Antimicrob Chemother 8, 413–416 (1981).
 29. Hasan, T., Sallum, U. W. & Verma, S. Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same 
(2009).
 30. Overdevest, I. T., Willemsen, I., Elberts, S., Verhulst, C. & Kluytmans, J. A. Laboratory detection of extended-spectrum-beta-
lactamase-producing Enterobacteriaceae: evaluation of two screening agar plates and two confirmation techniques. J Clin Microbiol 
49, 519–522 (2011).
 31. Hrabak, J., Chudackova, E. & Papagiannitsis, C. C. Detection of carbapenemases in Enterobacteriaceae: a challenge for diagnostic 
microbiological laboratories. Clin Microbiol Infect 20, 839–853 (2014).
 32. Pitout, J. D., Le, P. G., Moore, K. L., Church, D. L. & Gregson, D. B. Detection of AmpC beta-lactamases in Escherichia coli, Klebsiella 
spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory. Clin Microbiol Infect 16, 165–170 (2010).
 33. Brooks, W. L. & Sumerlin, B. S. Synthesis and Applications of Boronic Acid-Containing Polymers: From Materials to Medicine. 
Chem Rev 116, 1375–1397 (2016).
 34. Das, B. C. et al. Boron chemicals in diagnosis and therapeutics. Future Med Chem 5, 653–676 (2013).
 35. Baroni, M., Cruciani, G., Sciabola, S., Perruccio, F. & Mason, J. S. A common reference framework for analyzing/comparing 
proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J. Chem. Inf. Model. 47, 279–294 
(2007).
 36. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important 
macromolecules. J. Med. Chem. 28, 849–857 (1985).
 37. http://www.moldiscovery.com.
 38. Quotadamo, A. et al. An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases. Synkett 27, 2447–2450 (2016).
 39. Naas, T., Dortet, L. & Iorga, B. Structural and functional aspects of class A carbapenemases. Curr. Drug Targets, in press, (2015).
 40. Borgianni, L. et al. Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. 
Antimicrob Agents Chemother 54, 3197–3204 (2010).
 41. Lahiri, S. D. et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in 
complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases. Antimicrob. Agents Chemother. 57, 2496–2505 
(2013).
 42. Liang, Z. et al. Molecular basis of NDM-1, a new antibiotic resistance determinant. PLoS One 6, e23606 (2011).
 43. Ourghanlian, C., Soroka, D. & Arthur, M. Inhibition by Avibactam and Clavulanate of the beta-Lactamases KPC-2 and CTX-M-15 
Harboring the Substitution N132G in the Conserved SDN Motif. Antimicrob Agents Chemother 61, (2017).
www.nature.com/scientificreports/
1 4SCIENTIFIC REPORTS |  (2017) 7:17716  | DOI:10.1038/s41598-017-17399-7
 44. Quero, G. et al. Long period fiber grating working in reflection mode as valuable biosensing platform for the detection of drug 
resistant bacteria. Sensors and Actuators B: Chemical 230, 510–520 (2016).
 45. Santillana, E., Beceiro, A., Bou, G. & Romero, A. Crystal structure of the carbapenemase OXA-24 reveals insights into the 
mechanism of carbapenem hydrolysis. Proc Natl Acad Sci USA 104, 5354–5359 (2007).
 46. Powers, R. A. et al. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. 
Protein. Sci. 8, 2330–2337 (1999).
 47. Mobley, D. L. & Dill, K. A. Binding of small-molecule ligands to proteins: “what you see” is not always “what you get”. Structure 17, 
489–498 (2009).
 48. Chen, Y., Shoichet, B. & Bonnet, R. Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases. J. 
Am. Chem. Soc. 127, 5423–5434 (2005).
 49. Levitt, M. & Perutz, M. F. Aromatic rings act as hydrogen bond acceptors. J. Mol. Biol. 201, 751–754 (1988).
 50. Ke, W., Bethel, C. R., Thomson, J. M., Bonomo, R. A. & van den Akker, F. Crystal structure of KPC-2: insights into carbapenemase 
activity in class A beta-lactamases. Biochemistry 46, 5732–5740 (2007).
 51. Institute, C. a. L. S. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement M100–S209, 
(2010).
 52. Kumalo, H. M., Bhakat, S. & Soliman, M. E. Theory and applications of covalent docking in drug discovery: merits and pitfalls. 
Molecules 20, 1984–2000 (2015).
 53. Lei, M., Zhao, X., Wang, Z. & Zhu, Y. Pharmacophore modeling, docking studies, and synthesis of novel dipeptide proteasome 
inhibitors containing boron atoms. J. Chem. Inf. Model. 49, 2092–2100 (2009).
 54. Li, X. et al. A Statistical Survey on the Binding Constants of Covalently Bound Protein–Ligand Complexes. Molecular Informatics 
29, 87–96 (2010).
 55. Ghiglione, B. et al. Structural and Kinetic Insights into the “Ceftazidimase” Behavior of the Extended-Spectrum beta-Lactamase 
CTX-M-96. Biochemistry 54, 5072–5082 (2015).
 56. Drawz, S. M., Papp-Wallace, K. M. & Bonomo, R. A. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. 
Antimicrob. Agents Chemother. 58, 1835–1846 (2014).
 57. Krishnan, N. P., Nguyen, N. Q., Papp-Wallace, K. M., Bonomo, R. A. & van den Akker, F. Inhibition of Klebsiella beta-Lactamases 
(SHV-1 and KPC-2) by Avibactam: A Structural Study. PLoS One 10, e0136813 (2015).
 58. Cartwright, S. J. & Waley, S. G. Purification of beta-lactamases by affinity chromatography on phenylboronic acid-agarose. Biochem. 
J. 221, 505–512 (1984).
 59. Usher, K. C., Blaszczak, L. C., Weston, G. S., Shoichet, B. K. & Remington, S. J. Three-dimensional structure of AmpC beta-lactamase 
from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor 
design. Biochemistry 37, 16082–16092 (1998).
 60. Docquier, J. D. et al. CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the 
Caulobacter crescentus chromosome. Antimicrob Agents Chemother 46, 1823–1830 (2002).
 61. Burlingham, B. & Widlanski, T. An Intuitive Look at the Relationship of Ki and IC50: A More General Use for the Dixon Plot. J 
Chem Educ 80, 214 (2003).
 62. Brem, J. et al. Structural Basis of Metallo-beta-Lactamase Inhibition by Captopril Stereoisomers. Antimicrob Agents Chemother 60, 
142–150 (2015).
 63. Carosati, E., Sciabola, S. & Cruciani, G. Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic 
data to a new angular function in the GRID force field. J. Med. Chem. 47, 5114–5125 (2004).
 64. Fortuna, C. G. et al. New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens. Eur. J. Med. Chem. 
65, 533–545 (2013).
 65. Muratore, G. et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral 
polymerase. Proc. Natl. Acad. Sci. USA 109, 6247–6252 (2012).
 66. Muratore, G. et al. Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses. Antimicrob. 
Agents Chemother. 56, 6009–6013 (2012).
 67. Spyrakis, F. et al. A pipeline to enhance ligand virtual screening: integrating Molecular Dynamics and FLAP. J. Chem. Inf. Model. 
(2015).
 68. Spyrakis, F. et al. Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis. ChemMedChem 9, 
1501–1511 (2014).
 69. Spyrakis, F. et al. Isozyme-specific ligands for O-acetylserine sulfhydrylase, a novel antibiotic target. PLoS One 8, e77558 (2013).
 70. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; 25th informational 
supplement., CLSI M100-S125 (2015).
Acknowledgements
This work was supported by the OPTObacteria project within the 7FP (Grant agreement no: 286998; www.
optobacteria.eu), and by the National Institute of Health (Grant no: GM63815). JB was supported by the Spanish 
Network for Research in Infectious Pathology (REIPI) RD12/0015/0012, funded by Ministerio de Economía y 
Competitividad, Instituto de Salud Carlos III, and co-financed by the European Development Regional Fund “A 
way to achieve Europe” ERDF. We also acknowledge the members of REIPI for providing the bacterial isolates.
Author Contributions
M.S. and F.D.L. produced and purified the β-lactamase enzymes. A.Q., D.F. and A.V. performed the synthesis of 
the compounds. M.S. performed the enzyme inhibition assays. F.S. run the in silico simulations. S.C. implemented 
the software. A.I.P., C.I. and J.B. performed the microbiological analyses. M.S., D.T., F.S., S.C., J.D.D. and M.P.C. 
wrote the manuscript. M.P.C., A.V. and G.C. conceived the work. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-17399-7.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 5SCIENTIFIC REPORTS |  (2017) 7:17716  | DOI:10.1038/s41598-017-17399-7
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
